New drug aims to lock in remission for rare lymphoma
NCT ID NCT07647432
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections for up to 6 cycles. The main goals are to see if patients can complete the treatment and whether it improves remission rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab
What this could lead to
If it works, this could point toward a way to keep plasmablastic lymphoma from coming back after initial treatment.
What could go wrong
This is a very small, early feasibility study with only 17 participants, so results may not apply broadly. Elranatamab can cause serious side effects like cytokine release syndrome and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••